Nanjing Hanxin Pharmaceutical Technology Co.,Ltd. was established in 2017, which is also a member of the US listed group Amphastar Pharmaceuticals. Hanxin is committed to becoming an international industry benchmark for "research and development, manufacturing, and sales of biopharmaceuticals, innovative drugs and complex formulations ". Hanxin has a core technical team with rich industry experience and familiarity with domestic and foreign drug regulations, providing one-stop solutions for R&D, small-scale testing, pilot-scale testing, and commercial manufacturing of various products for innovative drug research institutions.

High-standard laboratory base:

Hanxin has a modern R&D building with an area of 13,000 square meters, including various laboratories such as fermentation, purification, peptide, synthesis, enzyme catalysis, formulation, and analysis, equipped with various advanced instruments and equipment worth more than 100 million yuan.

International quality system:

Hanxin has aquality system that meets international standards and can simultaneously meet filings in China and the United States.

R&D team with Chinese and American experience and intellectual property management team:

There are nearly 200 employees. The core technical team has more than 10 years of project experience.

International Project Experience:

Hanxin has developed over 100 projects for more than 50 domestic and international pharmaceutical companies, covering various disease fields such as pediatrics, endocrinology, emergency medicine, local anesthesia, hematology, pneumology, and orthopedics. Among them, four finished products developed for clients have been approved by FDA, and 21 DMFs have been submitted; Two Class 1 new drugs haveentered Phase I clinical trials under CDE review.

Parent Company

Amphastar Pharmaceuticals Group

Founded in 1996, headquartered in California, USA.

It develops, produces, and sells over 60 injectables and inhalers in accordance with FDA cGMP regulations. The company listed on the NASDAQ in 2014 (stock code: AMPH). Its subsidiaries are located in the United States, China, and Europe, with over 200,000 square meters of factories and over 2,000 employees.

Holding subsidiary

Nanjing Cuccess Pharmaceutical Co., Ltd.

Hanxin Pharm acquired 51% share of Nanjing Cuccess Pharmaceutical in September 2021.

Address: No. 20, Xingang Avenue, Nanjing Economic and Technological Development Zone.

Registered capital: USD9 million

Fixed assets: 105,000m2 land, with total construction area of 54,800m2

Employees: 400+,   including production, registration, quality, sales and management teams

Production lines and products: 13 GMP drug production lines, with 17 drug products on sale.

Marketing:The national sales network covers 6,000 hospitals and more than 100,000 terminals